For the Inventor, By the Inventor

Enter assignee name

Wilmington, DE, United States of America

The Dupont Merck Pharmaceutical Company

USPTO Granted Patents = 206

Trademarks = 1

Forward Citations = 3,183

Loading Chart...

Loading Chart...

231 inventors (with patents filed for the assignee):

Richard A Earl (15 out of 15 patents)

Wendell W Wilkerson (13 out of 17 patents)

Douglas G Batt (12 out of 54 patents)

4. Prabhakar Kondaji Jadhav (12 out of 27 patents)

5. Gary Avonn Cain (11 out of 18 patents)

6. Sang W Tam (11 out of 11 patents)

7. Joseph J Petraitis (10 out of 11 patents)

8. Christopher A Teleha (10 out of 10 patents)

9. John Wityak (9 out of 49 patents)

10. Jung-Hui Sun (9 out of 18 patents)

11. Richard Gerald Wilde (7 out of 18 patents)

12. Paul J Gilligan (7 out of 7 patents)

13. Michael J Orwat (6 out of 43 patents)

14. Charles A Kettner (6 out of 14 patents)

15. Richard Eric Olson (6 out of 108 patents)

Core Competencies:

Radiopharmaceutical Compositions

Neurotransmitter Release

Factor Xa Inhibitors

Platelet GPIIb/IIIa Antagonists

Stabilized Naloxone Formulations

Integrin Receptor Antagonists

Cyclic Urea Inhibitors

Hydroxamic Acid Compounds

Cognition Enhancers

Immunoassay Reagents

Thrombin Inhibitors

HIV Protease Inhibitors

206 patents: Sort by Forward Citations

1. 6348184 - Radiopharmaceutical compositions and matrices and uses thereof (2002-02-19),

2. 5990132 - Polycyclic systems, and derivatives thereof, as neurotransmitter release (1999-11-23),

3. 5939418 - Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors (1999-08-17),

4. 5879657 - Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents (1999-03-09),

5. 5866154 - Stabilized naloxone formulations (1999-02-02),

6. 5849736 - Isoxazoline and isoxazole fibrinogen receptor antagonists (1998-12-15),

7. 5849693 - Cyclic compounds linked by a heterocyclic ring useful as inhibitors of (1998-12-15),

8. 5811441 - Isoxazoline fibrinogen receptor antagonists (1998-09-22),

9. 5811422 - Substituted cyclic carbonyls and derivatives thereof useful as (1998-09-22),

10. 5773411 - Cyclic compounds linked by a heterocyclic ring useful as inhibitors of (1998-06-30),

11. 5769080 - Gas filled liposomes and stabilized gas bubbles and their use as (1998-06-23),

12. 5763469 - Substituted cyclic ureas and derivatives thereof useful as retroviral (1998-06-09),

13. 5760029 - Spirocycle integrin inhibitors (1998-06-02),

14. 5760028 - Integrin receptor antagonists (1998-06-02),

15. 5750528 - Blockade of neuronal m-channels as a therapeutic approach to the (1998-05-12),

The DuPont Merck Pharmaceutical Company is a leading global pharmaceutical company, specializing in the research, development, and manufacturing of innovative healthcare solutions. With a rich history of over 100 years, we are committed to improving the lives of patients worldwide. Our diverse product portfolio includes prescription drugs, biologics, and over-the-counter medications, addressing a wide range of therapeutic areas. We strive to deliver breakthrough treatments and therapies to advance patient care and contribute to the well-being of communities. Visit our website to learn more about our company and the healthcare solutions we offer.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

206 Patents

#34 in Wilmington, DE

#46 in Delaware

#1,940 in US

#4,003 in the World

Wilmington, DE, United States of America

The Dupont Merck Pharmaceutical Company

Forward Citations = 3,183

231 inventors:

Richard A Earl (15 out of 15 patents)

Wendell W Wilkerson (13 out of 17 patents)

Douglas G Batt (12 out of 54 patents)

4. Prabhakar Kondaji Jadhav (12 out of 27 patents)

5. Gary Avonn Cain (11 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…